Janux <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports third quarter net loss of $24.3 million
Janux Therapeutics Inc. reported cash and cash equivalents and short-term investments of $989.0 million as of September 30, 2025, compared to $1.0 billion at December 31, 2024. Research and development expenses for the third quarter of 2025 were $34.6 million, up from $18.6 million in the same period in 2024. General and administrative expenses were $10.6 million, compared to $17.7 million for the third quarter of 2024, with the previous year's figure including $9.5 million in stock-based compensation expense. Net loss for the quarter ended September 30, 2025, was $24.3 million, compared to $28.1 million in the prior year period. During the period, Janux continued enrollment for its Phase 1 clinical trials of JANX007 in metastatic castration-resistant prostate cancer and JANX008 in advanced or metastatic solid tumors. Additional data updates for both programs are expected in the fourth quarter of 2025. The company is also advancing additional candidates from its TRACTr, TRACIr, and ARM platforms toward future clinical development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Janux Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106163122) on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.